CTMX — CytomX Therapeutics Share News
0.000.00%
Last trade - 00:00- $531.67m
- $201.39m
- $76.20m
U.S. STOCKS ON THE MOVE-Foot Locker, Nemaura, Chipotle
U.S. STOCKS ON THE MOVE-TD Synnex, Nucor, Pfizer
U.S. STOCKS ON THE MOVE-Xerox, AC Immune, OpGen
CytomX rises on $5 mln milestone payment
Brief: CytomX Announces Milestone Achievement In Probody TCB Collab With Astellas
U.S. STOCKS ON THE MOVE-Gold miners, Silver miners, BlackRock
CytomX rises after $35 mln licensing deal with Moderna
U.S. RESEARCH ROUNDUP- Humana, JP Morgan, Voya Financial
CytomX surges on $35 mln licensing deal with Moderna
Brief: Cytomx Therapeutics Provides Business Update And Outlines 2023 Company Priorities
Moderna, CytomX to collaborate on mRNA-based therapies (updated)
Moderna, CytomX announce mRNA collaboration
Brief: Cytomx Therapeutics To Outline 2023 Company Priorities And Provide Pipeline Update On January 5, 2023
U.S. STOCKS ON THE MOVE-CytomX, Immunic, Macy's
Brief: Cytomx And Regeneron Announce Strategic Research Collaboration In The Field Of Conditional Bispecific Therapeutics For The Treatment Of Cancer
CytomX soars on cancer therapies agreement with Regeneron
U.S. RESEARCH ROUNDUP-Amyris, HanesBrands, Roblox
Brief: CytomX Therapeutics Reports Q3 2022 Results
CytomX Therapeutics Inc reports results for the quarter ended in September - Earnings Summary